Abstract 1766P
Background
Urachal cancer is a rare genitourinary malignancy that is considered to be an aggressive cancer. There is a paucity of epidemiological data on this cancer.
Methods
Adults aged 20 years and older diagnosed with urachal cancer between 1988 and 2019 were identified through the California Cancer Registry (n = 315). Cancer occurrence across various sociodemographic characteristics (e.g., age, sex, race/ethnicity, neighborhood socioeconomic status (SES)) as well as tumor characteristics, initial treatment and survival were examined via frequency and percentage distributions. Kaplan Meier methods were used to calculate overall survival.
Results
Males represented 56.5% (n = 178) of cases. The majority of cases were non-Hispanic Whites (60.3%) followed by Hispanic (18.4%), Asian/Pacific Islander (14.3%), and non-Hispanic Black (6.0%). Most cases were diagnosed at regional stage (37.8%) followed by localized (32.7%) and metastatic disease (27.0%). Urachal cancer was the cause of death in 32.4% of cases followed by other cause (22.5%) and unknown cause (3.5%); 41.6% of patients were alive. Median overall survival (OS) for all patients was 76 months (95% CI, 50-109). Median OS was 178 months in patients with in situ/localized disease, 83 months in patients with regional disease, and 19 months in patients with metastatic disease. Table: 1766P
Characteristics of adults aged 20 and older diagnosed with urachal cancer in California, 1988-2019
| N | % | |
| Total | 315 | 100 |
| Sex | ||
| Male | 178 | 56.5% |
| Female | 137 | 43.5% |
| Race/Ethnicity | ||
| Non-Hispanic White | 190 | 60.3% |
| Non-Hispanic Black | 19 | 6.0% |
| Hispanic | 58 | 18.4% |
| Asian/Pacific Islander | 45 | 14.3% |
| American Indian/Other | 3 | 0.95% |
| Stage at diagnosis | ||
| Localized | 103 | 32.7% |
| Regional | 119 | 37.8% |
| Metastatic | 85 | 27.0% |
| Unknown | 8 | 2.5% |
Conclusions
This is the largest known study of urachal cancer. Approximately one-third of patients had distant metastatic disease at the time of diagnosis. Patients with localized and regional disease lived longer than those with metastatic disease. The study’s findings provide new insight into the demographics and survival of this rare genitourinary malignancy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Rezazadeh Kalebasty: Financial Interests, Personal, Stocks/Shares: ECOM Medical; Financial Interests, Personal, Advisory Role: Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics, Gilead Sciences; Financial Interests, Personal, Speaker’s Bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences, AVEO; Financial Interests, Personal, Research Grant: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioCin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics, Epizyme; Financial Interests, Personal, Other: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis, AstraZeneca. All other authors have declared no conflicts of interest.